BREAKING
Siggy launches out of stealth with $6 million pre-seed funding
The platform combines monthly human clinician appointments with an AI agent that monitors patient progress and tracks daily health metrics between visits.
AI-enabled virtual mental health provider Siggy has launched out of stealth with $6 million in pre-seed funding to expand its continuous care platform. The round was backed by venture firm Village Global alongside a group of individual angel investors.
The startup, which operates across all 50 US states, pairs monthly appointments with human clinicians with an AI therapy agent designed to maintain patient engagement between visits.
| Detail | Status | Source |
|---|---|---|
| Funding round | $6 million pre-seed | Company launch |
| Key investors | Village Global, undisclosed angels | Company launch |
| Coverage area | All 50 US states | Company launch |
| Post-money valuation | Not disclosed | Company launch |
Why it matters
For digital health founders and investors, Siggy is testing whether combining AI tools with human clinical oversight can fix one of psychiatric care's most persistent problems: patient drop-off.
Around 16 per cent of American adults take antidepressants, but one-fifth stop their treatment before completing the recommended course. By handling patient intake, running daily check-ins, and monitoring treatment adherence, Siggy aims to keep patients engaged between traditional monthly consultations without increasing human clinical overhead.
How the platform works
Patients begin with a free, anonymous conversation with Siggy's AI interface without creating an account or logging in. The system retains their history to ensure patients do not need to repeat information in future consultations.
An AI-generated preliminary diagnosis is passed to human clinicians, who review the findings and present treatment options to the patient. Patients pay only if they choose to proceed with treatment.
After an initial consultation with a human healthcare provider, patients can invite existing doctors or family members to join the system and establish their treatment goals. Those who enrol meet with a human clinician once a month and interact with the AI assistant between visits.
Between appointments, the AI therapy agent uses the patient's history to assist with treatment goals, remind them of prescribed exercises, and track progress. The AI is programmed not to answer medical questions, routing clinical queries to human clinicians, and includes safety protocols to flag high-acuity cases immediately.
Siggy also integrates with wearable devices and conducts a one-minute daily check-in to track sleep, mood, physical health, and medication side effects. These inputs generate a daily "Siggy Score" on a scale of 0 to 100, visible to both the patient and clinician. During the first two months, weekly check-ins allow doctors to assess whether to maintain, adjust, or taper medication dosages. Siggy can prescribe medications, excluding controlled substances.
"It can build a really detailed picture of you rather fast, and the idea is if there are behavior patterns that are recurrent, Siggy can begin to help people gain agency and recognize them before they happen," Siggy co-founder and chief executive officer Jonathan Sabbagh told reporters.
Founders and insurance coverage
Sabbagh co-founded Siggy after spending two decades in finance, subsequently studying psychology and co-founding Journey Clinical, a psychedelic-assisted therapy network in the US.
He built Siggy alongside chief operating officer Dr Edvard Engesaeth, who previously co-founded digital health platform Nurx, and chief medical officer Dr Daniel Montville, a Mayo Clinic-trained psychiatrist.
Siggy is covered by major commercial insurance providers in all 50 US states, including Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Humana. The platform also accepts Medicaid, Medicare, and TRICARE, and offers its services free of charge to military veterans.
What comes next
In the longer term, Siggy plans to integrate speech analytics, laboratory results, genetic testing, and biomarkers into its diagnostic model to identify other conditions, including diabetes and amyotrophic lateral sclerosis (ALS).
The company also intends to develop neural datasets designed to support clinical trials for emerging health technologies, including brain implants.
Siggy has not disclosed its valuation following the pre-seed round or the full list of participating angel investors.